Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Melanie Mediavilla-Varela"'
Optimization of In Vitro Th17 Polarization for Adoptive Cell Therapy in Chronic Lymphocytic Leukemia
Autor:
Wael Gamal, Melanie Mediavilla-Varela, Angimar Uriepero-Palma, Javier Pinilla-Ibarz, Eva Sahakian
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 12, p 6324 (2024)
Although preclinical investigations have shown notable efficacy in solid tumor models utilizing in vitro-differentiated Th17 cells for adoptive cell therapy (ACT), the potential benefits of this strategy in enhancing ACT efficacy in hematological mal
Externí odkaz:
https://doaj.org/article/b4dfe0ff5d9f4008bdf10b43d459e4ed
Publikováno v:
Proceedings, Vol 100, Iss 1, p 19 (2024)
Transcription factors bind specific DNA motifs to regulate the expression of target genes in order to maintain normal hematopoiesis [...]
Externí odkaz:
https://doaj.org/article/e2dad4ac88dc4d56a01b5248197082b1
Autor:
Kamira Maharaj, John J. Powers, Melanie Mediavilla-Varela, Alex Achille, Wael Gamal, Steven Quayle, Simon S. Jones, Eva Sahakian, Javier Pinilla-Ibarz
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Development of chronic lymphocytic leukemia (CLL) is associated with severe immune dysfunction. T-cell exhaustion, immune checkpoint upregulation, and increase of regulatory T cells contribute to an immunosuppressive tumor microenvironment. As a resu
Externí odkaz:
https://doaj.org/article/6d90ade24c674ca0b70cd526e4ee4350
Autor:
Melanie Mediavilla-Varela, Julio Castro, Alberto Chiappori, David Noyes, Dalia C. Hernandez, Bertrand Allard, John Stagg, Scott J. Antonia
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 19, Iss 7, Pp 530-536 (2017)
BACKGROUND: Therapeutic strategies targeting immune checkpoint proteins have led to significant responses in patients with various tumor types. The success of these studies has led to the development of various antibodies/inhibitors for the different
Externí odkaz:
https://doaj.org/article/1e09019f9dbb4076babae1b44dda43c7
Autor:
Anamika Basu, Christina K Cajigas-Du Ross, Leslimar Rios-Colon, Melanie Mediavilla-Varela, Tracy R Daniels-Wells, Lai Sum Leoh, Heather Rojas, Hiya Banerjee, Shannalee R Martinez, Stephanny Acevedo-Martinez, Carlos A Casiano
Publikováno v:
PLoS ONE, Vol 11, Iss 1, p e0146549 (2016)
Prostate cancer (PCa) mortality is driven by highly aggressive tumors characterized by metastasis and resistance to therapy, and this aggressiveness is mediated by numerous factors, including activation of stress survival pathways in the pro-inflamma
Externí odkaz:
https://doaj.org/article/178d5abb953b482b89f90f838bdba422
Autor:
Edna Gordian, Jiannong Li, Yuri Pevzner, Melanie Mediavilla-Varela, Kimberly Luddy, Kim Ohaegbulam, Kenyon G Daniel, Eric B Haura, Teresita Muñoz-Antonia
Publikováno v:
PLoS ONE, Vol 9, Iss 12, p e114131 (2014)
Lung cancer is the second most common cancer and the leading cause of cancer-related deaths. Despite recent advances in the development of targeted therapies, patients with advanced disease remain incurable, mostly because metastatic non-small cell l
Externí odkaz:
https://doaj.org/article/7e42a4b873b24b1bab2cc7677f01f5d9
Autor:
Melanie Mediavilla-Varela, Eva Sahakian, Carly Harro, John J. Powers, Jose Conejo-Garcia, Lubomir Sokol, Javier Pinilla Ibarz
Publikováno v:
Blood. 140:11880-11881
Autor:
Angimar Uriepero, Melanie Mediavilla-Varela, Kamira Maharaj, Wael Gamal, Maria Elena Marquez, John J. Powers, Vishaal Kunta, Eva Sahakian, Pablo Oppezzo, Javier Pinilla Ibarz
Publikováno v:
Blood. 140:6988-6989
Autor:
Wael Gamal, Melanie Mediavilla-Varela, Kamira Maharaj, Angimar Uriepero, Vishaal Kunta, Eva Sahakian, Javier Pinilla Ibarz
Publikováno v:
Blood. 140:6994-6995
Autor:
Eva Sahakian, Dave Maryanski, Andrii Monastyrskyi, Kamira Maharaj, Karen L. Burger, Hari P. Miskin, Kun Jiang, Derek R. Duckett, John L. Cleveland, William R. Roush, Wael Gamal, Melanie Mediavilla-Varela, Renee Fonseca, Alex Achille, Javier Pinilla-Ibarz, John Powers
Publikováno v:
Blood Adv
The in-clinic phosphatidylinositol 3-kinase (PI3K) inhibitors idelalisib (CAL-101) and duvelisib (IPI-145) have demonstrated high rates of response and progression-free survival in clinical trials of B-cell malignancies, such as chronic lymphocytic l